Novartis Financial Statements

Novartis (NOVARTIND) reported revenue of ₹3.56B in FY2025 with net income of ₹1.01B. Total assets stood at ₹9.48B and free cash flow was ₹745.70M.

Novartis Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		4.14B	4.00B	3.79B	3.35B	3.56B
Cost of Rev. Cost of Revenue		-1.47B	-1.96B	-1.97B	-1.80B	-1.95B
Gross Profit		2.68B	2.03B	1.82B	1.55B	1.61B
SGA Sales, General & Admin		-2.08B	-1.02B	-356.40M	-229.60M	-187.20M
Op. Income Operating Income		477.20M	-8.00M	637.20M	823.70M	967.30M
PBT Profit Before Tax		400.40M	-38.20M	1.15B	1.23B	1.30B
Net Income		209.00M	-37.20M	1.03B	851.90M	1.01B
Dil. Shares Diluted Shares		24.69M	24.69M	24.69M	24.69M	24.69M
Diluted EPS		8.46	-1.51	41.86	34.50	40.87

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Novartis's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Novartis Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		7.24B	7.09B	6.77B	6.99B	7.46B
Non-curr. assets Total non-current assets		2.78B	2.49B	3.06B	2.26B	2.02B
Total assets		10.02B	9.58B	9.83B	9.25B	9.48B
Curr. liabilities Total current liabilities		1.59B	2.16B	1.59B	1.57B	1.42B
Non-curr. liab. Total non-current liabilities		1.32B	494.50M	477.90M	229.10M	208.00M
Total liabilities		2.91B	2.66B	2.07B	1.80B	1.63B
Total equity		7.11B	6.92B	7.76B	7.45B	7.85B
Total liab. & eq. Total liabilities & equity		10.02B	9.58B	9.83B	9.25B	9.48B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Novartis's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Novartis Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		400.40M	-38.20M	1.15B	1.23B	1.30B
Operating CF Cash flow Operating Activities		-692.10M	386.70M	448.00M	1.13B	745.70M
Capex Investments in PPE		-900,000	-5.00M	-3.10M	0	0
Investing CF Cash flow Investing Activities		951.60M	870.40M	-1.53B	331.30M	-33.10M
Dividend Paid		-246.90M	-246.90M	-246.90M	-1.17B	-617.30M
Financing CF Cash flow Financing Activities		-368.00M	-356.30M	-304.80M	-1.21B	-641.50M
Cash (start) Cash at beginning of period		791.20M	682.70M	1.58B	194.20M	449.60M
Cash (end) Cash at end of period		682.70M	1.58B	194.20M	449.60M	520.70M
FCF Free Cash Flow		-693.00M	381.70M	444.90M	1.13B	745.70M

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Novartis's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025